The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Interventions for valvular disease and heart failure
Edwards SAPIEN 3 implanted in a failing aortic bioprosthesis: first report
EuroIntervention 2016;11:e1321 published online e-edition February 2016. DOI: 10.4244/EIJV11I11A255
Javier Molina-Martin de Nicolas, MD; Didier Tchetche*, MD; Bruno Farah, MD
Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France
An 87-year-old female was admitted for symptomatic failure of a 23 mm Carpentier-Edwards PERIMOUNT aortic bioprosthesis (Edwards Lifesciences, Irvine, CA, USA) implanted 17 years previously. Both severe central regurgitation and severe stenosis (mean gradient 60 mmHg) were identified. Due to a significant perioperative risk of redo surgery (EuroSCORE 46.5%, STS 7.3%), the Heart Team decided on transfemoral valve-in-valve (ViV) implantation. A 23 mm Edwards SAPIEN 3 (S3) device (Edwards Lifesciences) was chosen, based on a measured inner diameter of 20.5 mm by multislice computed tomography (MSCT) and of 21 mm as reported by the manufacturer. The ViV procedure was performed under conscious sedation and fluoroscopy guidance. The ...